QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, January 12, 2005, 25(2):409-416; doi:10.1523/JNEUROSCI.4054-04.2005

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (26) Citing Articles via Google Scholar Google Scholar Articles by Xie, J. Y. Articles by Vanderah, T. W. Search for Related Content PubMed PubMed Citation Articles by Xie, J. Y. Articles by Vanderah, T. W.

 Previous Article  |  Next Article 

Behavioral/Systems/Cognitive
Cholecystokinin in the Rostral Ventromedial Medulla Mediates Opioid-Induced Hyperalgesia and Antinociceptive Tolerance

Jennifer Y. Xie,¹ David S. Herman,¹ Carl-Olav Stiller,² Luis R. Gardell,¹ Michael H. Ossipov,¹ Josephine Lai,¹ Frank Porreca,¹ and Todd W. Vanderah¹

¹Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, Arizona 85724, and ²Division of Clinical Pharmacology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden SE-17176

Opioid-induced hyperalgesia is characterized by hypersensitivity to innocuous or noxious stimuli during sustained opiate administration. Microinjection of lidocaine into the rostral ventromedial medulla (RVM), or dorsolateral funiculus (DLF) lesion, abolishes opioid-induced hyperalgesia, suggesting the importance of descending pain facilitation mechanisms. Here, we investigate the possibility that cholecystokinin (CCK), a pronociceptive peptide, may drive such descending facilitation from the RVM during continuous opioid administration. In opioid-naive rats, CCK in the RVM produced acute tactile and thermal hypersensitivity that was antagonized by the CCK₂ receptor antagonist L365,260 or by DLF lesion. CCK in the RVM also acutely displaced the spinal morphine antinociceptive dose-response curve to the right. Continuous systemic morphine elicited sustained tactile and thermal hypersensitivity within 3 d. Such hypersensitivity was reversed in a time-dependent manner by L365,260 in the RVM, and blockade of CCK₂ receptors in the RVM also blocked the rightward displacement of the spinal morphine antinociceptive dose-response curve. Microdialysis studies in rats receiving continuous morphine showed an approximately fivefold increase in the basal levels of CCK in the RVM when compared with controls. These data suggest that activation of CCK₂ receptors in the RVM promotes mechanical and thermal hypersensitivity and antinociceptive tolerance to morphine. Enhanced, endogenous CCK activity in the RVM during sustained morphine exposure may diminish spinal morphine antinociceptive potency by activating descending pain facilitatory mechanisms to exacerbate spinal nociceptive sensitivity. Prevention of opioid-dose escalation in chronic pain states by CCK receptor antagonism represents a potentially important strategy to limit unintended enhanced clinical pain and analgesic tolerance.

Key words: cholecystokinin; CCK₂ receptor; opioid hyperalgesia; antinociceptive tolerance; morphine; rostral ventromedial medulla; microdialysis; L365,260

---

Received June 14, 2004; revised November 18, 2004; accepted November 19, 2004.

This article has been cited by other articles:

				L. S. Stone and D. C. Molliver In Search of Analgesia: Emerging Poles of GPCRs in Pain Mol. Interv., October 1, 2009; 9(5): 234 - 251. [Abstract] [Full Text] [PDF]

				W. Zhang, S. Gardell, D. Zhang, J. Y. Xie, R. S. Agnes, H. Badghisi, V. J. Hruby, N. Rance, M. H. Ossipov, T. W. Vanderah, et al. Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors Brain, March 1, 2009; 132(3): 778 - 787. [Abstract] [Full Text] [PDF]

				M. P. Davis and M. Angst In Reply J. Clin. Oncol., July 10, 2008; 26(20): 3465 - 3465. [Full Text] [PDF]

				M. P. Davis and M. Angst In Reply J. Clin. Oncol., March 20, 2008; 26(9): 1565 - 1565. [Full Text] [PDF]

				M. P. Davis, L. A. Shaiova, and M. S. Angst When Opioids Cause Pain J. Clin. Oncol., October 1, 2007; 25(28): 4497 - 4498. [Full Text] [PDF]

				M. Vosoughian, A. Dabbagh, S. Rajaei, and H. Maftuh The Duration of Spinal Anesthesia with 5% Lidocaine in Chronic Opium Abusers Compared with Nonabusers Anesth. Analg., August 1, 2007; 105(2): 531 - 533. [Abstract] [Full Text] [PDF]

				W. Kincaid, M. J. Neubert, M. Xu, C. J. Kim, and M. M. Heinricher Role for Medullary Pain Facilitating Neurons in Secondary Thermal Hyperalgesia J Neurophysiol, January 1, 2006; 95(1): 33 - 41. [Abstract] [Full Text] [PDF]

				A. Dogrul, E. J. Bilsky, M. H. Ossipov, J. Lai, and F. Porreca Spinal L-Type Calcium Channel Blockade Abolishes Opioid-Induced Sensory Hypersensitivity and Antinociceptive Tolerance Anesth. Analg., December 1, 2005; 101(6): 1730 - 1735. [Abstract] [Full Text] [PDF]

				J. C. Roberts, B. M. Grocholski, K. F. Kitto, and C. A. Fairbanks Pharmacodynamic and Pharmacokinetic Studies of Agmatine after Spinal Administration in the Mouse J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1226 - 1233. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help